Literature DB >> 24885209

Distribution of superantigens in group A streptococcal isolates from Salvador, Brazil.

Hillary F Berman, Sara Yee Tartof, Joice N Reis, Mitermayer G Reis, Lee W Riley1.   

Abstract

BACKGROUND: Group A streptococcus (GAS) causes invasive disease, superficial disease, and can asymptomatically colonize humans. Superantigens are one virulence factor found in GAS. Previous studies found associations between the genes that encode superantigens and emm type of GAS. It is unknown if these associations are due to underlying biological factors that limit the distribution of superantigens or, alternatively, if these associations are due to the expansion of local GAS linages where these studies took place. To further address this question we screened GAS isolates collected from Salvador, Brazil for 11 known superantigen genes.
METHODS: Seventy-seven GAS isolates were screened by PCR for superantigen genes. These superantigen genes were speA, speC, speG, speH, speI, speJ, speK, speL, speM, ssa, and smeZ. We used Fisher's two-sided exact test to identify associations between superantigens and GAS emm type. We then compared our results to previous reports of superantigen prevalence and superantigen association with emm type.
RESULTS: In our collection we found several emm type and superantigen genotype combinations that have previously been reported in isolates from Europe and Australia. We also found that speA was significantly associated with emm type 1, and that speC was significantly associated with emm type 12.
CONCLUSIONS: Our study reports superantigen genotypes of GAS from a region of the world that is lacking this information. We found evidence of common GAS superantigen genotypes that are spread worldwide as well as novel superantigen genotypes that, so far, are unique to Brazil.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24885209      PMCID: PMC4045995          DOI: 10.1186/1471-2334-14-294

Source DB:  PubMed          Journal:  BMC Infect Dis        ISSN: 1471-2334            Impact factor:   3.090


Background

Streptococcus pyogenes (Group A Streptococcus, or GAS) is a Gram positive bacterium that causes a wide spectrum of clinical manifestations including pharyngitis, skin infections, necrotizing fasciitis, and streptococcal toxic shock syndrome [1]. GAS harbors many virulence factors including superantigens [1]. Superantigens are bacterial exotoxins that are able to activate large numbers of T cells [1-3]. There are eleven known superantigens found in S. pyogenes: SpeA, SpeC, SpeG, SpeH, SpeI, SpeJ, SpeK, SpeL, SpeM, SSA, and SmeZ [4]. Superantigen genotype varies by emm type and the region of the world in which the isolate was collected [5,6]. An area of active research is whether these associations are due to factors that limit the distribution of superantigens or are due to the expansion of local GAS linages [7]. To further address this question we studied a collection of GAS isolates from Brazil. Previous studies of superantigens in GAS isolates from this region of the world are limited and none of these studies have reported the genotypes of all eleven superantigens [8]. Some superantigens are encoded by genes located in the prophage region of the GAS genome. Others are encoded by genes located outside of this region and are considered to be chromosomally encoded [7,9,10]. The SpeA, speC, SpeH, speI, speK, speL, speM and ssa genes have been found within prophages in streptococcal isolates [4,7,11]. The speG, SpeJ, and smeZ genes are considered to be encoded chromosomally [9,12]. The aim of this project was to determine if associations between superantigens, superantigen genotypes, and emm types that have been reported elsewhere were also found in our collection of Group A streptococcus isolates collected from Salvador, Brazil. These isolates were collected as part of a previous study of Group A Streptococcus in children with and without pharyngitis [13,14]. From this previously published study we selected all isolates of the two most common emm types (emm 1 and emm 12) and the emm type with the strongest association with pharyngitis (emm 66) to genotype [13].

Methods

Isolate collection and emm typing

S. pyogenes isolates were collected and emm typing was conducted as part of a separate cross-sectional study detailed elsewhere [13,14]. Briefly, isolates were collected from three hospital clinics in Salvador, Brazil. Patients between the ages of three and fifteen were recruited from the middle of April 2007 to end of October 2008 [13,14]. As described in previous publications, Institutional Review Board (IRB) approval was obtained from all hospitals, the Comissão Nacional de Ética em Pesquisa (Conep) (National Bioethics Commission of Brazil), the Comitê de Ética em Pesquisa-Centro de Pesquisa Gonçalo Moniz-Fiocruz (Ethics Committee for Research - Fiocruz), and the University of California, Berkeley Committee for the Protection of Human Subjects [13,14]. As previously described consent was obtained from parents or guardians and verbal consent was obtained from children [13,14]. Isolates were collected from children who had pharyngitis (strep throat) and those who were asymptomatic carriers of GAS. Emm typing of all isolates was performed as described by the Center for Disease Control and Prevention (CDC) protocol http://www.cdc.gov/ncidod/biotech/strep/protocol_emm-type.htm. We selected the two most common emm types (emm 1; n = 25 and emm 12; n = 40) as well as the emm type with strongest association with pharyngitis (emm 66; n = 12) to analyze for superantigen genes. For the purposes of this analysis the emm 1.25 isolate (n = 1) was included with emm 1.

Superantigen identification by PCR

Superantigen genes were identified by PCR using primers previously published by Maripuu et al. or Commons et al.[6,15] (Table  1). The Commons et al. primers were used to identify speB (a positive control for DNA quality), speJ, speK, speH, speL, and speM. The Maripuu et al. primers were used to identify speA, speC, speG, speI, ssa, and smeZ. Each 20 μl PCR mixture contained 1 U of taq DNA polymerase (New England Biolabs, Ipswich, MA), 0.25 mM DNTPs (New England Biolabs, Ipswich, MA), 1X ThermoPol buffer (New England Biolabs, Ipswich, MA), 1 μl template DNA, and 1 nanomole of the forward and reverse primer. Template DNA was extracted with the Qiagen DNEasy kit as previously described [13]. The cycling program for the Commons et al. primers was as follows: 2 minutes at 95°C, 35 cycles of 30 seconds at 94°C, 30 seconds at 50°C, 60 seconds at 72°C, and a final extension for 2 minutes at 72°C. The cycling program used for Maripuu et al. was as follows: 5 minutes at 94°C, 25 cycles of 30 seconds at 94°C, 30 seconds at primer specific annealing temperature, 60 seconds at 72°C, and a final extension of 7 minutes at 72°C. As a positive control for each superantigen gene PCR, we used the DNA of an isolate known to contain the relevant superantigen gene. We were unable to amplify speL from any isolate and therefore were unable to generate a positive control for speL.
Table 1

Primers used

GeneForward primer (5′ to 3′)Reverse primer (5′ to 3′)Annealing temp. °CProduct size (bp)
speA1-3,6 [15]
5′-GGACTAACAATCTCGCAAGAGG-3′
5′-TTACTTGGTTGTTAGGTAGACTTC-3′
54
696
speA4,5 [15]
5′-GCTAACAACCTCACAAGAAG -3′
5′-TGCTTGAGTCAAGCGTCTC-3′
53
659
speC[15]
5′-GATTTCTACTATTTCACC-3′
5′-AAATATCTGATCTAGTCCC-3′
44
584
speG[15]
5′-CTTATGCAGATGAAAATTTAAAAGATT-3′
5′-AAAGCAAAGGGGGGAGAATAG-3′
53.2
664
speI[15]
5′-ATGAGTAGTGTGGGAGTTATTAA-3′
5′-ATGAAGTTGATCAGAATAAGCG-3′
55
645
speJ[15]
5′-ATCTTATTTAGTCCAAAGGTAAAT-3′
5′-GTGAACGAGGAGAGGTATGAA-3′
55.5
718
smeZ[15]
5′-TTGGATTAGAAGTAGATAA-3′
5′-TTGAATTAGGAGTCAATTTCTATATCT-3′
52
638
ssa[15]
5′-AGTCAGCCTGACCCTACTCCA-3′
5′-TAAGGTGAACCTCTATAGCTATAG-3′
59.1
691
speH[6]
5′-TTGGATCCAATTCTTATAATACAACC-3′
5′-CCACTTCCTGAGCGGTTACTTTCGG-3′
50
399
speJ[6]
5′-CTATGGTGGAATTACACC-3′
5′-CATGTTTATTGCCATTGATCGC-3′
50
247
speK[6]
5′-GCGGATCCGATACGTACAATACAAATG-3′
5′-GCGAATTCAATAGCATTCAACCA-3′
50
798
speL[6]
5′-GCAGCCATATGGAAGAGACTATTCCTCTTAAGGATATATACTCTC-3′
5′-GGGGATCCTTAATTTTCTTTGTTTGTGAATAAATAGAC-3′
50
703
speM[6]
5′-GCAGCCATATGTTTTCAGATGCTGTGTTGG-3′
5′-GGGGATCCTTAATTTTTAGAAAAATCTTCGTTTAAGTA-3′
50
661
speB[6]5′-GGATCCCAACCAGTTGTTAAATCTCT-3′5′-AACGTTCTAAGGTTTGATGCCTACAA-3′50774

All primer sequences shown here have previously been published by Maripuu et al. or Commons et al.

Primers used All primer sequences shown here have previously been published by Maripuu et al. or Commons et al.

Literature review

To the best of our knowledge, we included all studies in our literature review that tested for the presence or absence of the GAS superantigen genes that showed variability in our study. These superantigens are speA, speC, speI, speJ, speM, and ssa. We excluded any studies in which superantigen genotypes of individual isolates could not be determined.

Data analysis

The associations between superantigens and categorical variables were analyzed by Fisher’s two-sided exact test. STATA (StataCorp, Version 10) was used for all analyses.

Results and discussion

Distribution of superantigen genes

We identified speA, speC, speG, speH, speI, speJ, speM, ssa, and smeZ gene sequences from at least one isolate. We did not find any isolates with speK or speL in the collection (Table  2). The most common gene, speG, was present in all isolates. The smeZ gene was present in 99% of 77 isolates. The least common superantigen genes that were identified in at least one strain were speM, found in 5% isolates, and ssa, found in 8% isolates.
Table 2

Distribution of superantigens by type

 Total (N = 77)emm1 (N = 25)emm12 (N = 40)emm66 (N = 12)P-value
speA
32 (42%)
25 (100%)
1 (3%)
6 (50%)
p < .001
speC
33 (43%)
0
33 (83%)
0
p < .001
speG
77 (100%)
25 (100%)
40 (100%)
12 (100%)
 
speH
28 (36%)
0
22 (55%)
6 (50%)
p < .001
speI
48 (62%)
4 (16%)
37 (93%)
7 (58%)
p < .001
speJ
11 (14%)
9 (36%)
1 (3%)
1 (8%)
p < .001
speK
0
0
0
0
 
speL
0
0
0
0
 
speM
4 (5%)
1 (4%)
3 (8%)
0
 
ssa
6 (8%)
1 (4%)
4 (10%)
1 (8%)
 
smeZ76 (99%)25 (100%)40 (100%)11 (92%) 
Distribution of superantigens by type The speA genes in emm 1 strains were identified by the Maripuu et al. speA 1–3, 6 primers. The speA genes in emm 12 and emm 66 strains were identified by the Maripuu et al. speA-4, 5 primers, indicating they were different alleles. The prevalence of superantigen genes varied across emm type (Table  2). The speA gene was found in 100% of emm 1 isolates, 50% of emm 66 isolates, and in only 3% of emm 12 isolates (p < .001). SpeC was found in 83% of emm 12 isolates and in no emm 1 or emm 66 isolates (p < .001). The speH gene was found in 55% of emm 12 isolates, 50% of emm 66 isolates, and in no emm 1 isolates (p < .001). The speI gene was found in 93% of emm 12 isolates, 58% of emm 66 isolates, and in 16% of emm 1 isolates (p < .001). The speJ gene was found in 3% of emm 12 isolates, 8% of emm 66 isolates, and in 36% of emm 1 isolates (p < .001).

Superantigen-emm genotyping

We examined the diversity of superantigen genotypes within the same emm type. We were able to distinguish 20 distinct strains of GAS using superantigen genotypes alone (Table  3). The three emm types we examined in this study were further divided into 24 distinct genotypes by the combination of emm typing and superantigen genotype. We reviewed previously reported emm 1, 12, and 66 superantigen genotypes and found many genotypes have been given multiple names. For further reference, we have included the original citation and superantigen genotype name from all studies included in our literature review (Table  4). For the subsequent analysis all the genotypes names used are from Table  3.
Table 3

Superantigen genotype and distribution across type

Genotype speA speC speG speH speI speJ speK speL speM ssa smeZ emm12 (40)emm1 (25)emm66 (12)p-value
A (n = 1)
X
 
X
 
X
 
 
 
X
 
X
0
1 (4%)
0
 
B (n = 17)
X
 
X
 
 
 
 
 
 
 
X
0
13 (52%)
4 (33.3%)
<.001
C (n = 1)
X
 
X
 
 
X
 
 
 
X
X
0
1 (4%)
0
 
D (n = 7)
X
 
X
 
 
X
 
 
 
 
X
0
7 (28%)
0
<.001
E (n = 3)
X
 
X
 
X
 
 
 
 
 
X
0
2 (8%)
1 (8.3%)
 
F (n = 1)
X
 
X
 
X
X
 
 
 
 
X
0
1 (4%)
0
 
G (n = 1)
 
 
X
X
X
 
 
 
X
 
X
1 (2.5%)
0
0
 
H (n = 2)
 
X
X
X
X
 
 
 
 
X
X
2 (5%)
0
0
 
J (n = 19)
 
X
X
X
X
 
 
 
 
 
X
19 (47.5%)
0
0
<.001
K (n = 3)
 
X
X
 
 
 
 
 
 
 
X
3 (7.5%)
0
0
 
M (n = 2)
 
X
X
X
X
 
 
 
X
 
X
2 (5%)
0
0
 
N (n = 8)
 
 
X
X
X
 
 
 
 
 
X
5 (12.5%)
0
3 (25%)
 
O (n = 1)
X
X
X
X
X
 
 
 
 
 
X
1 (2.5%)
0
0
 
P (n = 1)
 
 
X
 
 
 
 
 
 
 
X
0
0
1 (8.3%)
 
Q (n = 4)
 
X
X
 
X
 
 
 
 
 
X
4 (10%)
0
0
 
R (n = 1)
 
X
X
X
X
X
 
 
 
 
X
1 (2.5%)
0
0
 
S (n = 1)
 
X
X
 
X
 
 
 
 
X
X
1 (2.5%)
0
0
 
T (n = 1)
 
 
X
X
X
X
 
 
 
 
 
0
0
1 (8.3%)
 
U (n = 2)
 
 
X
X
X
 
 
 
 
X
X
1 (2.5%)
0
1 (8.3%)
 
V (n = 1)X XXX     X001 (8.3%) 

Superantigen genotypes B and D were found significantly more often in emm type 1 isolates. Superantigen genotype J was found significantly more often in emm type 12 isolates. P-values were generated with the two-sided Fisher’s exact test.

Table 4

Previously reported superantigen genotypes

GenotypespeAspeCspeGspeHspeIspeJspeKspeLspeMssasmeZOthernameCountriesemmYear
A (n = 1)
X
 
X
 
X
 
 
 
X
 
X
None
 
 
 
B (n = 17)
X
 
X
 
 
 
 
 
 
 
X
R
Australia
1
2001-2002 [6]
 
 
 
 
 
 
 
 
 
 
 
 
A
Sweden
1
1989 [15]
C (n = 1)
X
 
X
 
 
X
 
 
 
X
X
F
Australia
1
2001-2001 [6]
D (n = 7)
X
 
X
 
 
X
 
 
 
 
X
D
Australia
1
2001-2002 [6]
 
 
 
 
 
 
 
 
 
 
 
 
C
Sweden
1
1988-2001 [15]
 
 
 
 
 
 
 
 
 
 
 
 
Not Given
Norway
1
2006-2007 [16]
 
 
 
 
 
 
 
 
 
 
 
 
Not Given
New Zealand
1
Not given [17]
 
 
 
 
 
 
 
 
 
 
 
 
Not Given
Spain
1
1999-2003 [18]
 
 
 
 
 
 
 
 
 
 
 
 
I
Norway
1
1988-2003 [19]
 
 
 
 
 
 
 
 
 
 
 
 
Not Given
Sweden
1
2006-2007 [20]
E (n = 3)
X
 
X
 
X
 
 
 
 
 
X
None
 
 
 
F (n = 1)
X
 
X
 
X
X
 
 
 
 
X
None
 
 
 
G (n = 1)
 
 
X
X
X
 
 
 
X
 
X
None
 
 
 
H (n = 2)
 
X
X
X
X
 
 
 
 
X
X
D
China
1
2005-2006 [21]
 
 
 
 
 
 
 
 
 
 
 
 
D
China
12
1993-1994, 2005-2006 [21]
J (n = 19)
 
X
X
X
X
 
 
 
 
 
X
H
Australia
12
2001-2002 [6]
 
 
 
 
 
 
 
 
 
 
 
 
S3
Sweden
12
1989-1993 [15]
 
 
 
 
 
 
 
 
 
 
 
 
Not Given
Norway
12
2006-2007 [16]
 
 
 
 
 
 
 
 
 
 
 
 
Not Given
Spain
12
1999-2003 [18]
 
 
 
 
 
 
 
 
 
 
 
 
VII
Norway
12
1988-2003 [19]
 
 
 
 
 
 
 
 
 
 
 
 
S26
Sweden
66
1989 [15]
K (n = 3)
 
X
X
 
 
 
 
 
 
 
X
None
 
 
 
M (n = 2)
 
X
X
X
X
 
 
 
X
 
X
None
 
 
 
N (n = 8)
 
 
X
X
X
 
 
 
 
 
X
J
Australia
12
2001-2002 [6]
 
 
 
 
 
 
 
 
 
 
 
 
Not Given
Norway
12
2006-2007 [16]
 
 
 
 
 
 
 
 
 
 
 
 
Not Given
Spain
12
1999-2003 [18]
 
 
 
 
 
 
 
 
 
 
 
 
AC
Sweden
66
1988-1990 [15]
O (n = 1)
X
X
X
X
X
 
 
 
 
 
X
None
 
 
 
P (n = 1)
 
 
X
 
 
 
 
 
 
 
X
None
 
 
 
Q (n = 4)
 
X
X
 
X
 
 
 
 
 
X
None
 
 
 
R (n = 1)
 
X
X
X
X
X
 
 
 
 
X
Not Given
ATCC
1
Not given [17]
S (n = 1)
 
X
X
 
X
 
 
 
 
X
X
None
 
 
 
T (n = 1)
 
 
X
X
X
X
 
 
 
 
 
Not Given
New Zealand
12
Not given [17]
U (n = 2)
 
 
X
X
X
 
 
 
 
X
X
T
Australia
12
2001-2002 [6]
 
 
 
 
 
 
 
 
 
 
 
 
Not Given
Spain
12
1999-2003 [18]
V (n = 1)X XXX     XNone   

Previously published emm 1, 12 and 66 superantigen genotypes were reviewed and compared to our collection. “Genotype” refers to designations given in this paper. “Other name” refers to pattern name given in previously published work. Citations refer to the reference section.

Superantigen genotype and distribution across type Superantigen genotypes B and D were found significantly more often in emm type 1 isolates. Superantigen genotype J was found significantly more often in emm type 12 isolates. P-values were generated with the two-sided Fisher’s exact test. Previously reported superantigen genotypes Previously published emm 1, 12 and 66 superantigen genotypes were reviewed and compared to our collection. “Genotype” refers to designations given in this paper. “Other name” refers to pattern name given in previously published work. Citations refer to the reference section. The most common superantigen genotype, J, contained 19 isolates. The second most common genotype, B, contained 17 isolates. Genotype J was exclusively found in emm 12, and represented 48% of all emm 12 isolates (p < .001). Genotype B was significantly associated with emm 1 (p < .001) but was also found in 4 emm 66 isolates. Genotype D was exclusively found in emm 1 isolates (p < .001).

Discussion

In this study speA and speJ were significantly associated with emm 1. speH and speI were significantly less likely to be found in emm 1 isolates as compared to the rest of the collection (Table  2). Previous studies also found that speA is frequently found in emm type 1 GAS isolates [6,15,22,23]. We found that superantigen genotype B and superantigen genotype D comprised the majority of emm 1 isolates. Genotype B and genotype D differ only by the presence of speJ in genotype D. Genotype B has previously been reported in emm 1 isolates from Australia between 1989 and 2002 [6]. Genotype D has previously been reported exclusively in emm 1 isolates. These isolates were collected in Norway, Spain, New Zealand, and Australia between 1988 and 2003 [6,15,16,18,19]. In this study speC was significantly associated with emm 12 and was not found in either emm 1 or emm 66 isolates. Previous studies found speC is often found in emm 12 isolates including isolates from China and Japan [23,24]. However, in contrast to the results of the current study, the studies of isolates from China and Japan have found that speC is also present in the emm1 isolates from these same collections [23,24]. In the current study, the majority of emm 12 isolates had superantigen genotype J. Genotype J has previously been reported in emm 12 and 66 from Norway, Spain, and Australia between 1989 and 2007, indicating that this particular genotype is very common and has spread worldwide [6,15,16,18,19]. There were no statistically significant associations of superantigens with emm 66. Only 12 emm 66 isolates were included in this study and the sample size may have been too small to produce meaningful results.

Conclusions

Previous studies found superantigens are not randomly distributed across emm types [6,15,22]. However, associations between specific superantigens and emm types often vary by study. Previous studies have suggested numerous hypotheses to explain this variation. It is unknown if this variation is due to underlying biological factors that limit the distribution of superantigens, the selective advantage due to carrying particular superantigens, or the chance expansion of local GAS clones at the time these studies took place. This is an area of active research [7,11]. The current study helps to address this question by reporting the superantigen genotypes of GAS isolated from a region of the world from which information on superantigen genotypes is lacking. This is the first study to report the prevalence of all 11 superantigens in a collection of isolates from South America or Brazil. Similar to other previously published work we found some common genotypes of GAS which are spread world wide as well as novel genotypes of GAS which have only been reported in this study.

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

HB and ST carried out the lab work and statistical analysis required for the study. HB drafted the manuscript. LW, JR, and MR provided critical review of the manuscript and participated in the study designed. All authors read and approved the final manuscript.

Pre-publication history

The pre-publication history for this paper can be accessed here: http://www.biomedcentral.com/1471-2334/14/294/prepub
  24 in total

1.  Toxin-gene profile heterogeneity among endemic invasive European group A streptococcal isolates.

Authors:  Franz-Josef Schmitz; Andreas Beyer; Emmanuelle Charpentier; Birgitta Henriques Normark; Marc Schade; Ad C Fluit; Dieter Hafner; Rodger Novak
Journal:  J Infect Dis       Date:  2003-11-05       Impact factor: 5.226

Review 2.  Streptococcus pyogenes: Insight into the function of the streptococcal superantigens.

Authors:  Shiranee Sriskandan; Lee Faulkner; Philip Hopkins
Journal:  Int J Biochem Cell Biol       Date:  2006-09-01       Impact factor: 5.085

3.  Dynamics in prophage content of invasive and noninvasive M1 and M28 Streptococcus pyogenes isolates in The Netherlands from 1959 to 1996.

Authors:  Bart J M Vlaminckx; Frank H J Schuren; Roy C Montijn; Martien P M Caspers; M M Beitsma; Wim J B Wannet; Leo M Schouls; Jan Verhoef; Wouter T M Jansen
Journal:  Infect Immun       Date:  2007-04-23       Impact factor: 3.441

Review 4.  The bacterial superantigen and superantigen-like proteins.

Authors:  John D Fraser; Thomas Proft
Journal:  Immunol Rev       Date:  2008-10       Impact factor: 12.988

5.  Superantigen gene profile diversity among clinical group A streptococcal isolates.

Authors:  Linda Maripuu; Anna Eriksson; Mari Norgren
Journal:  FEMS Immunol Med Microbiol       Date:  2008-08-27

6.  Superantigen genes in group A streptococcal isolates and their relationship with emm types.

Authors:  Robert Commons; Susan Rogers; Travis Gooding; Margie Danchin; Jonathan Carapetis; Roy Robins-Browne; Nigel Curtis
Journal:  J Med Microbiol       Date:  2008-10       Impact factor: 2.472

7.  Superantigen-induced T cell responses in acute rheumatic fever and chronic rheumatic heart disease patients.

Authors:  A Bhatnagar; A Grover; N K Ganguly
Journal:  Clin Exp Immunol       Date:  1999-04       Impact factor: 4.330

8.  Molecular characterisation of group A streptococci from invasive and non-invasive disease episodes in Belgium during 1993-1994.

Authors:  P Descheemaeker; F VAN Loock; M Hauchecorne; P Vandamme; H Goossens
Journal:  J Med Microbiol       Date:  2000-05       Impact factor: 2.472

9.  Superantigen gene profile, emm type and antibiotic resistance genes among group A streptococcal isolates from Barcelona, Spain.

Authors:  Alba Rivera; Montserrat Rebollo; Elisenda Miró; Míriam Mateo; Ferran Navarro; Mercé Gurguí; Beatriz Mirelis; Pere Coll
Journal:  J Med Microbiol       Date:  2006-08       Impact factor: 2.472

10.  Severe group A streptococcal infections in Uppsala County, Sweden: clinical and molecular characterization of a case cluster from 2006 to 2007.

Authors:  Anna Vikerfors; Axana Haggar; Jessica Darenberg; Aili Low; Asa Melhus; Johan Hedlund; Staffan Sylvan; Anna Norrby-Teglund; Britt-Marie Eriksson
Journal:  Scand J Infect Dis       Date:  2009
View more
  4 in total

1.  Antibodies to the conserved region of the M protein and a streptococcal superantigen cooperatively resolve toxic shock-like syndrome in HLA-humanized mice.

Authors:  Manisha Pandey; Ainslie Calcutt; Victoria Ozberk; Zhenjun Chen; Matthew Croxen; Jessica Powell; Emma Langshaw; Jamie-Lee Mills; Freda E-C Jen; James McCluskey; Jenny Robson; Gregory J Tyrrell; Michael F Good
Journal:  Sci Adv       Date:  2019-09-04       Impact factor: 14.136

2.  Streptococcus pyogenes strains associated with invasive and non-invasive infections present possible links with emm types and superantigens.

Authors:  Rao Muhammad Abid Khan; Sana Anwar; Zaid Ahmed Pirzada
Journal:  Iran J Basic Med Sci       Date:  2020-01       Impact factor: 2.699

3.  Assessment of the Relationship between Clinical Manifestation and Pathogenic Potential of Streptococcus pyogenes Strains-Distribution of Genes and Genotypes of Toxins.

Authors:  Tomasz Bogiel; Alicja Domian; Zuzanna Dobrzyńska; Agnieszka Mikucka; Eugenia Gospodarek-Komkowska
Journal:  Biomedicines       Date:  2022-03-29

4.  A Multiplex Assay for Detection of Staphylococcal and Streptococcal Exotoxins.

Authors:  Preeti Sharma; Ningyan Wang; Adam S Chervin; Cheryl L Quinn; Jennifer D Stone; David M Kranz
Journal:  PLoS One       Date:  2015-08-25       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.